Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation

Table 1 Other main diagnosis excluding atrial fibrillation in the studied sample

Diagnosis	n	%
AMI	1973	48.19
Cardiac arrhythmias	210	5.37
Chest pain	201	4.91
Heart failure	143	3.49
Chronic coronary syndrome	80	1.95
Cardiomyopathies	77	1.88
Peripheral artery disease	74	1.81
Stable angina	55	1.34
Unstable angina	45	1.10
Pericarditis	29	0.71
Valvular heart diseases	27	0.66
Shock	21	0.51
Pulmonary embolism	22	0.49
Other	233	15.65

AMI: Acute myocardial infarction.

Table 2 Secondary cardiac and extra-cardiac diagnoses in the studied sample

Secondary diagnosis	n	%
Cardiac
Chronic coronary syndromes	1864	45.51
Cardiomyopathies	1221	29.81
Valvular heart diseases	595	14.53
Heart failure	406	9.91
Arrhythmias	119	2.91
Angina pectoris	91	2.22
Extra-cardiac
Arterial hypertension	1010	24.66
Renal diseases	985	24.05
Diabetes mellitus	932	22.75
Lung diseases	617	15.06
Dyslipidemias	345	8.42
Cerebrovascular & psychiatric diseases	313	7.64
Thyroid diseases	152	3.71
Anemia	166	4.05
Peripheral artery diseases	146	3.56
Obesity	137	3.12
Neoplastic diseases	83	2.03

Table 3 Main diagnostic and therapeutic procedures performed in the studied sample

Procedures	n	%
Diagnostic
Echocardiogram	3588	87.60
Coronary angiography	804	19.63
Dynamic ECG monitoring	458	11.18
CT scan	299	7.30
Other echography	212	5.18
Stress test	139	3.39
Therapeutic
Coronary PTCA/stenting	941	22.97
PM implantation	258	6.30
ICD implantation	90	2.20
Peripheral vessels angiography	90	2.20
Peripheral vessels PTCA/stenting	60	1.46
Electric cardioversion	56	3.71

PTCA: Percutaneous transluminal coronary angioplasty; ECG: Electrocardiogram; CT: Computerized tomography; PM: Pacemaker; ICD: Implantable cardiac defibrillator.

Table 4 Changes in prescribed antithrombotic drugs over time in the studied group (absolute numbers)

Yr	Warfarin	Acenocumarole	Dabigatran	Rivaroxaban	Apixaban	Edoxaban	Aspirin	Clopidogrel	Ticlopidine	Ticagrelor	Prasugrel	LMWH	Fondaparinux	No therapy
2010	32	3					41	35	1			2		17
2011	93	3					82	30				2		24
2012	100	11					99	47				1		58
2013	177	12		2			191	73	7	7	1	17	4	65
2014	114	7		10			108	28		12		7	4	41
2015	149	12		18	11		138	40	5	13	1	20	1	55
2016	127	6		29	25	3	138	48		13	5	26		34
2017	116	17	18	24	46	16	95	63		7		9	6	30
2018	56	4	20	45	54	21	52	43		4		3	1	7
2019	43	4	40	40	67	21	68	55		2		3	2	2
2020	31	1	19	30	55	27	49	46		5		7	5	7
2021	15	2	29	17	46	41	35	35				4	2	8

LMWH: Low molecular weight heparin.